Crambescin C1 Exerts a Cytoprotective Effect on HepG2 Cells through Metallothionein Induction

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Farmacoloxíagl
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Fisioloxíagl
dc.contributor.authorRoel Sánchez, María
dc.contributor.authorRubiolo Gaytán, Juan Andrés
dc.contributor.authorTernon, Eva
dc.contributor.authorThomas, Olivier P.
dc.contributor.authorRodríguez Vieytes, Mercedes
dc.contributor.authorBotana López, Luis Miguel
dc.date.accessioned2020-11-09T09:14:12Z
dc.date.available2020-11-09T09:14:12Z
dc.date.issued2015
dc.description.abstractThe Mediterranean marine sponge Crambe crambe is the source of two families of guanidine alkaloids known as crambescins and crambescidins. Some of the biological effects of crambescidins have been previously reported while crambescins have undergone little study. Taking this into account, we performed comparative transcriptome analysis to examine the effect of crambescin-C1 (CC1) on human tumor hepatocarcinoma cells HepG2 followed by validation experiments to confirm its predicted biological activities. We report herein that, while crambescin-A1 has a minor effect on these cells, CC1 protects them against oxidative injury by means of metallothionein induction even at low concentrations. Additionally, at high doses, CC1 arrests the HepG2 cell cycle in G0/G1 and thus inhibits tumor cell proliferation. The findings presented here provide the first detailed approach regarding the different effects of crambescins on tumor cells and provide a basis for future studies on other possible cellular mechanisms related to these bioactivitiesgl
dc.description.peerreviewedSIgl
dc.description.sponsorshipFEDER cofunded-grants. CDTI and Technological Funds, supported by Ministerio de Economía y Competitividad, AGL2012-40185-CO2-01 and Consellería de Cultura, Educación e Ordenación Universitaria, GRC2013-016, and by Axencia Galega de Innovación, Spain, ITC-20133020 SINTOX, IN852A 2013/16-3 MYTIGAL. CDTIunderISIP Programme, Spain, IDI-20130304 APTAFOOD. European Union’s 7th Framework Programme managed by Research Executive Agency (FP7/2007-2013) under grant agreement Nos. 265409 µAQUA, 315285 CIGUATOOLS and 312184 PHARMASEAgl
dc.identifier.citationRoel, M.; Rubiolo, J.A.; Ternon, E.; Thomas, O.P.; Vieytes, M.R.; Botana, L.M. Crambescin C1 Exerts a Cytoprotective Effect on HepG2 Cells through Metallothionein Induction. Mar. Drugs 2015, 13, 4633-4653gl
dc.identifier.doi10.3390/md13084633
dc.identifier.essn1660-3397
dc.identifier.urihttp://hdl.handle.net/10347/23611
dc.language.isoenggl
dc.publisherMDPIgl
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/312184
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/315285
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/265409
dc.relation.publisherversionhttps://doi.org/10.3390/md13084633gl
dc.rights© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/)gl
dc.rightsAtribución 4.0 Internacional
dc.rights.accessRightsopen accessgl
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCrambescin-C1gl
dc.subjectCrambescin-A1gl
dc.subjectMetallothioneingl
dc.subjectCrambe crambegl
dc.subjectSponge-derived compoundsgl
dc.subjectTranscriptome profilinggl
dc.subjectAntioxidant effectgl
dc.subjectCell cycle inhibitiongl
dc.titleCrambescin C1 Exerts a Cytoprotective Effect on HepG2 Cells through Metallothionein Inductiongl
dc.typejournal articlegl
dc.type.hasVersionVoRgl
dspace.entity.typePublication
relation.isAuthorOfPublication6574bec8-97de-4fab-b2ba-d35b85751f34
relation.isAuthorOfPublication91f88e2e-ed1a-43f4-a16c-8d8d5c998e40
relation.isAuthorOfPublication9a18ed42-77b6-4760-8303-ff4070a87ca6
relation.isAuthorOfPublication.latestForDiscovery6574bec8-97de-4fab-b2ba-d35b85751f34

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2015_marinedrugs_roel_crambescin.pdf
Size:
4.84 MB
Format:
Adobe Portable Document Format
Description: